Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT + EGFR-TKI ± Radiotherapy in EGFR-Mutated NSCLC With Brain Metastasis
NCT07343479Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival rate at 6 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07343479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343479.